BLAINJECTIONINJECTABLE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERCESSI (trastuzumab-strf) is a monoclonal antibody biosimilar approved in April 2024 by Accord Biopharma. It is a trastuzumab reference product biosimilar indicated for HER2-positive breast cancer and gastric cancer treatment. The drug works by targeting HER2 receptors on cancer cells to inhibit tumor growth.
Growth
Early-stage biosimilar in growth phase with moderate competitive pressure (30); commercial teams are building market presence and establishing payer relationships.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HERCESSI offers entry and growth-stage career opportunities in biosimilar commercialization, particularly in payer strategy and field-based roles. Current linked job count is zero, but roles are expected to emerge as market launch activities accelerate.
Brand ManagerMedical Science Liaison
Worked on HERCESSI at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.